Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Cash Flows

v3.26.3
Condensed Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2026
Mar. 31, 2026
Sep. 30, 2025
Mar. 31, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Cash flows from operating activities:              
Net income (loss) $ (117,360) $ 1,299,135 $ 855,009 $ 967,796 $ 1,834,796 $ 1,916,168  
Adjustments to reconcile net income to net cash provided by operating activities:              
Depreciation and amortization         1,090,914 1,270,776  
Net loss on disposition or impairment         3,512,246 3,752,862  
Net franchise fees recognized upon termination of franchise agreements         (417,315) (257,797)  
Provision for credit losses         330,621 149,719 $ 286,232
Stock-based compensation expense         1,038,752 971,138  
Changes in operating assets and liabilities:              
Accounts receivable         288,722 1,464,026  
Prepaid expenses and other current assets         (794,596) (424,897)  
Deferred franchise costs         621,762 382,986  
Deposits and other assets         164,494 (19,280)  
Accounts payable         (897,087) (649,903)  
Accrued expenses         (1,227,636) (3,475,804)  
Payroll liabilities         (1,902,615) (925,440)  
Operating leases         (2,166,672) (3,843,956)  
Deferred revenue         (1,397,169) (1,643,696)  
Upfront regional developer fees         (286,597) (215,524)  
Other liabilities         794,968 489,649  
Net cash provided by (used in) operating activities         587,588 (1,058,973)  
Cash flows from investing activities:              
Proceeds from sale of clinics         1,426,000 7,778,287  
Purchase of property and equipment         (871,031) (1,154,385)  
Net cash provided by investing activities         554,969 6,623,902  
Cash flows from financing activities:              
Payments of finance lease obligation         0 (4,354)  
Purchases of treasury stock under employee stock plans         (76,818) (8,440)  
Purchases of common stock under stock repurchase programs         (5,646,397) (2,288,994)  
Proceeds from exercise of stock options         37,228 1,453,558  
Net cash used in financing activities         (5,685,987) (848,230)  
(Decrease) increase in cash, cash equivalents and restricted cash         (4,543,430) 4,716,699  
Cash, cash equivalents and restricted cash, beginning of period   $ 24,301,868   $ 25,996,436 24,301,868 25,996,436 25,996,436
Cash, cash equivalents and restricted cash, end of period 19,758,438   30,713,135   19,758,438 30,713,135 24,301,868
Reconciliation of cash, cash equivalents and restricted cash:              
Cash and cash equivalents 18,299,059   29,699,953   18,299,059 29,699,953 23,601,810
Restricted cash 1,459,379   1,013,182   1,459,379 1,013,182  
Cash, cash equivalents and restricted cash, end of period $ 19,758,438   $ 30,713,135   19,758,438 30,713,135 $ 24,301,868
Net cash paid for:              
Interest         37,917 37,917  
Income taxes, net of refunds         154,479 545,979  
Non-cash investing and financing activity:              
Unpaid purchases of property and equipment         0 91,883  
Notes receivable for the sale of clinics         $ 287,500 $ 0